Is Everest Organics overvalued or undervalued?

As of 17 November 2025, the valuation grade for Everest Organics has moved from fair to expensive. The company is currently considered overvalued, with a PE ratio of 65.86, an EV to EBITDA ratio of 28.46, and a Price to Book Value of 6.01. These figures indicate that the stock is trading at a significant premium compared to its earnings and book value.
In comparison to its peers, Everest Organics' valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 36.69, while Cipla is valued attractively with a PE of 22.81. The PEG ratio for Everest is also low at 0.32, suggesting that its growth prospects may not justify its current price. Notably, Everest Organics has outperformed the Sensex significantly in recent periods, with a year-to-date return of 49.14% compared to the Sensex's 8.72%.